In patients with CRC and potentially resectable liver metastases susceptible of conversion therapy, waiting time for KRAS test result must be adequate in order to ensure the eventual use of a monoclonal anti-EGFR antibody in combination with chemotherapy (Q1–12). The gene discussed is KRAS; the disease is colorectal carcinoma.